Cargando…
A New Treatment for Chronic Obstructive Pulmonary Disease: Ensifentrine Moves Closer
Autor principal: | Singh, Dave |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449076/ https://www.ncbi.nlm.nih.gov/pubmed/37433204 http://dx.doi.org/10.1164/rccm.202307-1164ED |
Ejemplares similares
-
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD
por: Donohue, James F, et al.
Publicado: (2023) -
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
por: Singh, Dave, et al.
Publicado: (2020) -
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
por: Anzueto, Antonio, et al.
Publicado: (2023) -
Physical activity and longevity: how to move closer to causal inference
por: Wade, Kaitlin H, et al.
Publicado: (2018) -
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis
por: Watz, Henrik, et al.
Publicado: (2020)